PAG
MIRM icon

Paladin Advisory Group’s Mirum Pharmaceuticals MIRM Stock Holding History

Paladin Advisory Group’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-131
Closed -$4.14K – 245
2023
Q3 		$4.14K Buy
+131
New +$3.59K ﹤0.01% 233

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Paladin Advisory Group's MIRM Position: Q4 2023 in Review

Paladin Advisory Group sold out of Mirum Pharmaceuticals (MIRM) in Q4 2023, closing a stake of 131 shares — an estimated $4.14K sold.

Paladin Advisory Group first reported a position in MIRM in Q3 2023 and held it in 1 quarter. The position peaked at $4.14K in Q3 2023. 187 funds tracked by Wall St. Rank hold MIRM as of Q4 2023.

  • Paladin Advisory Group reported no remaining Mirum Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Paladin Advisory Group sold 131 Mirum Pharmaceuticals shares in Q4 2023, an estimated $4.14K.
  • Paladin Advisory Group first reported a position in Mirum Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Paladin Advisory Group's Mirum Pharmaceuticals position peaked at $4.14K in Q3 2023.
  • 187 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2023.

Based on Paladin Advisory Group's 13F filing for Q4 2023, filed 31 Jan 2024.